Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AMG 397 in Relapsed/Refractory Hematological Malignancies
NCT03465540Phase 1Terminated
- Sponsor
- Amgen
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of murizatoclax in multiple myeloma (MM), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and 1 more (8 arms), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced a Dose-limiting Toxicity at 28 days and Number of Participants Who Experienced a Treatment-emergent Adverse Event. Started Aug 2018; status: terminated.
02
Drugs
murizatoclax
03
Conditions
multiple myeloma (MM)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03465540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465540.